Despite advanced therapeutic strategies, the mortality and morbidity of pancreatic cancer (PC) have been increasing. This is due to the anomalous proliferation activity of stromal cells, like cancer-associated fibroblasts (CAFs), in the tumor microenvironment (TME). These cells develop resistance in the tumor cells, blocking the drug from entering the target tumor site, ultimately resulting in tumor metastasis. Additionally, the current conventional adjuvant techniques, including chemo and radiotherapy, carry higher risk due to their excess toxicity against normal healthy cells. Phytochemicals including curcumin, irinotecan and paclitaxel are anti-oxidants, less toxic, and have anti-cancerous properties; however, the use of phytochemicals is limited due to their less solubility and bioavailability. Nanotechnology offers the resources to directly target the drug to the tumor site, thereby enhancing the therapeutic efficacy of the current treatment modalities. This review focuses on the importance of nanotechnology for pancreatic ductal adenocarcinoma (PDAC) therapy and on delivering the nano-formulated phytochemicals to the target site.

尽管采用了先进的治疗策略，但胰腺癌（PC）的死亡率和发病率一直在增加。这是由于肿瘤微环境 (TME) 中基质细胞（如癌症相关成纤维细胞 (CAF)）的异常增殖活性所致。这些细胞在肿瘤细胞中产生耐药性，阻止药物进入肿瘤靶位，最终导致肿瘤转移。此外，目前的传统辅助技术，包括化疗和放疗，由于对正常健康细胞的毒性过大而具有较高的风险。姜黄素、伊立替康和紫杉醇等植物化学物质具有抗氧化剂、毒性较低且具有抗癌特性；然而，植物化学物质的使用由于其溶解度和生物利用度较低而受到限制。纳米技术提供了将药物直接靶向肿瘤部位的资源，从而提高了当前治疗方式的治疗效果。本综述重点关注纳米技术对胰腺导管腺癌 (PDAC) 治疗的重要性以及将纳米配方植物化学物质输送到目标部位的重要性。